Federal Instititute for Drugs and Medical Device (BfArM), Bonn, Germany.
Eur J Med Res. 2009 Dec 7;14 Suppl 4(Suppl 4):216-26. doi: 10.1186/2047-783x-14-s4-216.
The European Directive 98/79/EC on in vitro diagnostic medical devices (IVD) stipulates the marketing and post market surveillance of IVD in the European Economic Area. In cases of issues and field corrective actions, the manufacturers have to inform the responsible Competent Authorities (CA). In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the responsible CA for most IVD, with a small subset of IVD for immune hematological and infectiological testing as well as tissue typing as specified in Annex II of the Directive, being within the responsibility of the Paul-Ehrlich-Institute (PEI). In this study, all issues regarding laboratory analyzers for infection testing and their consumables, but not reagents, kits and general culture media, reported to the BfArM between begin 1999 and end of 2007 were analyzed in respect to the sources of report, the underlying product failure and the performed corrective actions. Within the observation period a total of 1471 reports for IVD were received of which 73 related to the IVD for infection testing were included in our study. Reports were predominantly received from manufacturers (56) and competent authorities (15). Affected products were most frequently those for immunological analysis (42) whereas those based on culturing techniques (17) and molecular biological techniques (14) played only minor roles. In all these groups, laboratory analyzers (55) were more frequently affected than their consumables (18). Investigations of the manufacturers were able to identify the underlying root causes of product failures in 62 cases (84.9%). In 2 cases (2.7%) the root cause remained unclear and in 9 cases (12.3%) a product failure was excluded or a user error was the underlying cause. Product failures in laboratory analyzers were most frequently caused by software errors (31) and constructional faults (8) whereas the predominant cause of product failure in consumables were errors in production and quality control (8). Manufacturers issued corrective measures in 66 cases (90.4%) from which 49 and 17 were related to laboratory analyzers and their consumables, respectively. Based on the underlying root causes of product failures these were predominantly customer information (48), recalls (40), software-updates (30) and design changes (9) in the product group of laboratory analyzers as well as customer information (16), recalls (12) and modifications of production and quality management (11) in the group of consumables. The results and experiences obtained since 1999 suggest that the system for post marketing surveillance of IVD is an established tool to ensure product safety, even though the current system can be further enhanced.
欧洲指令 98/79/EC 规定了在体外诊断医疗器械 (IVD) 在欧洲经济区的市场和上市后监管。在出现问题和现场纠正措施的情况下,制造商必须通知负责的主管当局 (CA)。在德国,联邦药品和医疗器械研究所 (BfArM) 负责大多数 IVD,而指令附件 II 规定的免疫血液学和传染病学检测以及组织分型的一小部分 IVD 则由保罗-埃利希研究所 (PEI) 负责。在这项研究中,分析了 1999 年初至 2007 年底期间向 BfArM 报告的所有与感染检测实验室分析仪及其消耗品相关的问题,但不包括试剂、试剂盒和一般培养基,报告来源、潜在产品故障和采取的纠正措施。在观察期内,共收到 1471 份 IVD 报告,其中 73 份与感染检测的 IVD 相关,纳入本研究。报告主要来自制造商(56%)和主管当局(15%)。受影响的产品最常是免疫分析产品(42%),而基于培养技术(17%)和分子生物学技术(14%)的产品则相对较少。在所有这些组中,实验室分析仪(55%)比其消耗品(18%)更容易受到影响。制造商的调查能够确定 62 例(84.9%)产品故障的根本原因。在 2 例(2.7%)中,根本原因仍不清楚,在 9 例(12.3%)中,产品故障被排除或用户错误是根本原因。实验室分析仪产品故障最常由软件错误(31%)和结构故障(8%)引起,而消耗品产品故障的主要原因是生产和质量控制错误(8%)。制造商在 66 例(90.4%)中发布了纠正措施,其中 49 例和 17 例分别与实验室分析仪及其消耗品有关。基于产品故障的根本原因,实验室分析仪组主要是客户信息(48%)、召回(40%)、软件更新(30%)和设计变更(9%),消耗品组主要是客户信息(16%)、召回(12%)和生产质量管理变更(11%)。自 1999 年以来获得的结果和经验表明,IVD 上市后监管系统是确保产品安全的既定工具,尽管当前系统可以进一步改进。